Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | TET2 | Q6N021 | 6/20 | 0.32 |
| ▸ | TET3 | O43151 | 2/20 | 0.32 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.30 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
| ▸ | KDM4A | O75164 | 2/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.30 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6009469 | 0.82 | TET2 (0.47) | OR51E2SMN1; SMN2TET2TET3KDM4A | |
| SCHEMBL6009565 | 0.82 | OR51E2 (0.41) | OR51E2 | |
| SCHEMBL6009855 | 0.79 | OR51E2 (0.39) | OR51E2GABRR1 | |
| SCHEMBL6010162 | 0.78 | GSR (0.43) | OR51E2 | |
| SCHEMBL6009555 | 0.78 | RNPEP (0.42) | OR51E2LMNA | |
| SCHEMBL6009849 | 0.77 | CYP1A2 (0.46) | — | |
| SCHEMBL6010336 | 0.76 | OR51E2 (0.48) | OR51E2SMN1; SMN2PDE4A | |
| SCHEMBL28220236 | 0.76 | SLC1A1 (0.39) | OR51E2USP2SLCO1B1 | |
| SCHEMBL6010225 | 0.75 | OR51E2 (0.35) | OR51E2 | |
| SCHEMBL6010256 | 0.74 | SLC7A5 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | SEIWA KASEI COMPANY, LIMITED (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1584320-A1 | COSMETIC PREPARATION CONTAINING GLYCERYLAMINO ACID DERIVATIVE | Seiwa Kasei Company, Limited (JP) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | GLA, GPKOW, CUTA | OR51E2 2335/4885SMN1; SMN2 3951/4885SLC22A6 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.